Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer

Wanting Han; Mingyu Liu; Dong Han; Anthia A. Toure; Muqing Li; Anna Besschetnova; Zifeng Wang; Susan Patalano; Jill A. Macoska; Hung Ming Lam; Eva Corey; Housheng Hansen He; Shuai Gao; Steven P. Balk; Changmeng Cai

doi:10.1016/j.ymthe.2022.01.039

Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer

Wanting Han
, Mingyu Liu
, Dong Han
, Anthia A. Toure
, Muqing Li
, Anna Besschetnova
, Zifeng Wang
, Susan Patalano
, Jill A. Macoska
, Hung Ming Lam
, Eva Corey
, Housheng Hansen He
, Shuai Gao
, Steven P. Balk
, Changmeng Cai

Biology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1628-1644
Number of pages	17
Journal	Molecular Therapy
Volume	30
Issue number	4
DOIs	https://doi.org/10.1016/j.ymthe.2022.01.039
State	Published - Apr 6 2022

ASJC Scopus Subject Areas

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

Keywords

androgen deprivation therapy
androgen receptor
CDK4/6 inhibitor
DNA replication
E2F1
high-dose androgen
prostate cancer
Rb
retinoblastoma protein
transcriptional repression

Access to Document

10.1016/j.ymthe.2022.01.039

Cite this

Han, W., Liu, M., Han, D., Toure, A. A., Li, M., Besschetnova, A., Wang, Z., Patalano, S., Macoska, J. A., Lam, H. M., Corey, E., He, H. H., Gao, S., Balk, S. P., & Cai, C. (2022). Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Molecular Therapy, 30(4), 1628-1644. https://doi.org/10.1016/j.ymthe.2022.01.039

Han, W, Liu, M, Han, D, Toure, AA, Li, M, Besschetnova, A, Wang, Z, Patalano, S, Macoska, JA, Lam, HM, Corey, E, He, HH, Gao, S, Balk, SP & Cai, C 2022, 'Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer', Molecular Therapy, vol. 30, no. 4, pp. 1628-1644. https://doi.org/10.1016/j.ymthe.2022.01.039

@article{b363c3049f6f428a9bef46e19e9d3418,

title = "Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer",

keywords = "androgen deprivation therapy, androgen receptor, CDK4/6 inhibitor, DNA replication, E2F1, high-dose androgen, prostate cancer, Rb, retinoblastoma protein, transcriptional repression",

author = "Wanting Han and Mingyu Liu and Dong Han and Toure, \{Anthia A.\} and Muqing Li and Anna Besschetnova and Zifeng Wang and Susan Patalano and Macoska, \{Jill A.\} and Lam, \{Hung Ming\} and Eva Corey and He, \{Housheng Hansen\} and Shuai Gao and Balk, \{Steven P.\} and Changmeng Cai",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = apr,

day = "6",

doi = "10.1016/j.ymthe.2022.01.039",

language = "English",

volume = "30",

pages = "1628--1644",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer

AU - Han, Wanting

AU - Liu, Mingyu

AU - Han, Dong

AU - Toure, Anthia A.

AU - Li, Muqing

AU - Besschetnova, Anna

AU - Wang, Zifeng

AU - Patalano, Susan

AU - Macoska, Jill A.

AU - Lam, Hung Ming

AU - Corey, Eva

AU - He, Housheng Hansen

AU - Gao, Shuai

AU - Balk, Steven P.

AU - Cai, Changmeng

PY - 2022/4/6

Y1 - 2022/4/6

KW - androgen deprivation therapy

KW - androgen receptor

KW - CDK4/6 inhibitor

KW - DNA replication

KW - E2F1

KW - high-dose androgen

KW - prostate cancer

KW - Rb

KW - retinoblastoma protein

KW - transcriptional repression

UR - https://www.scopus.com/pages/publications/85124523126

UR - https://www.scopus.com/pages/publications/85124523126#tab=citedBy

U2 - 10.1016/j.ymthe.2022.01.039

DO - 10.1016/j.ymthe.2022.01.039

M3 - Article

C2 - 35121110

AN - SCOPUS:85124523126

SN - 1525-0016

VL - 30

SP - 1628

EP - 1644

JO - Molecular Therapy

JF - Molecular Therapy

IS - 4

ER -

Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this